Table 1. All outcome measures per group, time point and location.

		Controls	Anti-GPIb
CBF (ml/100 mg/min) 2 h vs. 24 h	Cortex	40.9±4.4 vs. 26.0±3.2	44.2±6.9 vs. 60.5±8.4
	Subcortex	33.6±4.3 vs. 24.8±3.2	45.3±5.9 vs. 46.9±7.5
ADC (mm2/s*10−4) 2 h vs. 24 h	Cortex	6.48±0.27 vs. 5.75±0.23	7.88±0.28 vs. 7.53±0.26
	Subcortex	6.08±0.60 vs. 5.29±0.33	7.86±0.33 vs. 7.12±0.26
qT2 (ms) 2 h vs. 24 h	Cortex	37.24±1.96 vs. 60.05±3.15	28.6±0.4 vs.29.0 ±0.97
	Subcortex	33.41±1.05 vs. 49.89±3.15	30.6±0.3 vs. 37.4±2.2
Probability of Infarction (%) 2 h vs. 24 h	Cortex	60.9±9.3 vs. 95.1±2.8	17.4±2.1 vs. 34.5±8.1
	Subcortex	79.1±9.9 vs. 100±0	21.5±7.9 vs. 64.8±14.5

Values are expressed as group means and corresponding standard errors. As the main finding sustained reperfusion was observed in anti-GPIb treated mice, whereas controls exhibited significant progression of hypoperfusion from 2 h to 24 h. In the cortex of the MCA territory, reperfusion significantly increased from 2 h to 24 h in anti-GPIb treated mice presumably related to a larger capacity of collateral blood flow as compared to the subcortex. In the subcortex of anti-GPIb treated mice, improved reperfusion as compared to controls was reflected by a significantly higher baseline CBF at 2 h. Sustained reperfusion both in the cortical and subcortical territory of the MCA was associated with a protection from cerebral infarction as evident by a low probability of infarction.